Cerus Corp

NASDAQ:CERSUnited States

Yesterday

Show headlines and story abstract

• -- Earnings Flash (CERS) CERUS CORPORATION Posts Q3 Revenue $50.7M, from 4:02PM ET on Wednesday Oct 30, 2024 by MT Newswires

  4:02PM ET on Wednesday Oct 30, 2024 by MT Newswires
  Companies Mentioned: CERS
  04:02 PM EDT, 10/30/2024 (MT Newswires) -- ...

• Cerus Corporation Announces Third Quarter 2024 Financial Results, from 4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones

  4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CERS
  Operating lease liabilities -- non-current 12,270 13,751 Other non-current liabilities 3,796 3,236 ----------- ---------- Total liabilities 135,258 144,304 ----------- ---------- Stockholders' equity: 53,489 52,650 ----------- ---------- Noncontrolling interest 792 794 ----------- ---------- Total liabilities and stockholders' equity $ 189,539 $ 197,748 =========== ========== CERUS CORPORATION UNAUDITED RECONCILIATION OF NON-GAAP ADJUSTED EBITDA (in thousands) Three Months Ended Nine Months Ended September 30 September 30 ------------------ ---------------------- 2024 2023 2024 2023 -------- -------- --------- ----------- Net loss attributable to Cerus Corporation $(2,934) $(7,267) $(18,397) $(36,161) Adjustments to net loss attributable to Cerus Corporation: Net loss attributable to noncontrolling interest - (19) (2) (97) Provision for income taxes 76 78 94 253 Total non-operating expense, net (i) 1,897 1,965 5,529 4,976 ------ ------ ------- ------- Loss from operations (961) (5,243) (12,776) (31,029) Adjustments to loss from operations: Operating depreciation and amortization 1,120 1,143 3,464 3,313 Government contract revenue (ii) (4,639) (7,479) (15,109) (23,856) Direct expenses attributable to government contracts (iii) 3,038 4,991 9,513 16,800 Share-based compensation (iv) 5,830 3,979 17,363 15,368 Costs attributable to noncontrolling interest (v) - 37 3 210 Restructuring (vi) - 1,600 - 3,728 ------ ------ ------- ------- Non-GAAP adjusted EBITDA $ 4,388 $ (972) $ 2,458 $(15,466) ====== ====== ======= ======= i. Includes interest income/expense and foreign exchange gains/losses. ii. Represents revenue related to the cost reimbursement provisions under our government contracts. iii. Represents the direct expenses attributable to work supporting government contracts, which are reimbursed and reflected under government contract revenue in the condensed consolidated statement of operations. iv. Represents non-cash stock-based compensation. v. Represents costs associated with the noncontrolling interest in Cerus Zhongbaokang (Shandong) Biomedical Co., LTD. vi. Represents costs associated with the Company's restructuring plan implemented in June 2023.
  

• *DJ Cerus 3Q Loss/Shr 2c >CERS, from 4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones

  4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CERS